Dopamine Transporters In Parkinson'S Disease is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dopamine transporters (DAT) are membrane proteins located on presynaptic dopaminergic neurons that are essential for dopamine reuptake from the synaptic cleft. In Parkinsons disease (PD), DAT is a critical biomarker for diagnosing the disease, monitoring its progression, and evaluating treatment responses. DAT imaging has revolutionized the understanding and management of parkinsonian disorders.
| Property | Value |
|---|---|
| Category | Molecular - Membrane Transporter |
| Location | Presynaptic terminals of dopaminergic neurons (substantia nigra pars compacta, ventral tegmental area) |
| Cell Type | Dopaminergic neurons |
| Neurotransmitter | Dopamine |
| Function | Dopamine reuptake, synaptic clearance, neurotransmission termination |
Dopamine transporter is a member of the neurotransmitter sodium symporter (NSS) family:
DAT operates via a sodium-dependent symport mechanism:
DAT provides rapid termination of dopaminergic signaling:
DAT activity is modulated by multiple mechanisms:
| Mechanism | Effect |
|---|---|
| Protein kinase C (PKC) | Downregulation |
| Protein kinase A (PKA) | Modulation |
| Calmodulin | Calcium-dependent regulation |
| Arachidonic acid | Activation |
| Neuropsychiatric drugs | Inhibition |
DAT exists in a dynamic equilibrium between:
In PD, DAT dysfunction is central to pathophysiology:
DAT deficiency
Diagnostic imaging
Differential diagnosis
Disease progression
DAT imaging shows characteristic patterns:
DAT imaging findings in MSA:
PSP shows distinct patterns:
DAT imaging evaluates:
| Tracer | Half-life | Use |
|---|---|---|
| [123I]FP-CIT (DaTscan) | 13.2 hours | Clinical diagnosis |
| [123I]β-CIT | 13.2 hours | Research |
| [99mTc]TRODAT-1 | 6 hours | Clinical |
| Tracer | Half-life | Use |
|---|---|---|
| [11C]CFT | 20 minutes | Research |
| [11C]d-threo-methylphenidate | 20 minutes | Research |
| [18F]FP-CIT | 110 minutes | Clinical |
DAT loss in PD results from:
Synucleinopathy
Mitochondrial dysfunction
Neuroinflammation
Potential DAT-protective approaches:
Dopamine transporters are essential membrane proteins that clear dopamine from the synaptic cleft, terminating dopaminergic neurotransmission. In Parkinsons disease, DAT loss in the nigrostriatal pathway is a hallmark of neurodegeneration. DAT neuroimaging has become invaluable for differential diagnosis, disease staging, and monitoring treatment responses. Understanding DAT biology provides insights into PD pathogenesis and opportunities for therapeutic intervention.
The study of Dopamine Transporters In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gainetdinov RR, Caron MG. Dopamine transporters. Methods in Enzymology (1999)
Jankovic J. DAT imaging in Parkinsons disease. Movement Disorders (2008)
Bohnen NI, Albin RL. Dopamine transporters in Parkinsonism. Movement Disorders (2011)
Stoessler MA. PET imaging of dopamine transporters. Radiology (1995)